Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

Executive Summary

FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.


Related Content

Pfizer’s Embeda Joins Abuse-Deterrent Club, But FDA Wants Assurances
Abuse-Deterrence Among New GDUFA Regulatory Science Priorities
No OxyContin Comparison? Then No Priority Review For Targiniq ER
Purdue’s Abuse-Deterrent Targiniq Is Different – Not Stronger – Than OxyContin
Opioid Abuse-Deterrent Labeling Claim Decision By FDA Could Come Soon
FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics
Purdue Execs’ Exclusion Stands But Court Tells HHS To Justify 12-Year Term
No Abuse-Resistance Claim For Endo’s Opana ER Reformulation
Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects
Purdue Execs Plead Guilty To Misbranding OxyContin; Company Pays $700 Mil.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts